PepGen (PEPG) Income from Continuing Operations (2021 - 2026)
PepGen (PEPG) reported Income from Continuing Operations of 17763000.0 for Q1 2026, up 41.19% on a YoY basis from 12581274.5 in Q1 2025, and up 2.89% sequentially from 18291000.0 in Q4 2025.
PepGen (PEPG) Income from Continuing Operations (2021 - 2026) Analysis & Trends
PepGen (PEPG) has 6 years of Income from Continuing Operations data on file, last reported at 17763000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 41.19% year-over-year to 17763000.0; the trailing twelve-month figure through Mar 2026 stood at 77167000.0 (up 24.92% YoY), and the FY2025 full-year result was 89655000.0, changed 0.36% from the prior year.
- Income from Continuing Operations improved to 17763000.0 in Q1 2026, from 18291000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 16319000.0 in Q1 2023 to a low of 46313000.0 in Q4 2022.
- A 5-year average of 22176529.41 and a median of 19422000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations slumped 4709.24% in 2022 and surged 58.06% in 2023, its largest moves.
- Tracing PEPG's Income from Continuing Operations over 5 years: stood at 46313000.0 in 2022, then surged by 58.06% to 19422000.0 in 2023, then declined by 17.7% to 22859000.0 in 2024, then gained by 19.98% to 18291000.0 in 2025, then grew by 2.89% to 17763000.0 in 2026.
- Business Quant data shows PEPG's Income from Continuing Operations at 17763000.0 in Q1 2026, 18291000.0 in Q4 2025, and 18026000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | PepGen | 145.09 Mn | 145.09 Mn | - | -17.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.76 Mn |
| Dec 31, 2025 | -18.29 Mn |
| Sep 30, 2025 | -18.03 Mn |
| Jun 30, 2025 | -23.09 Mn |
| Mar 31, 2025 | -30.20 Mn |
| Dec 31, 2024 | -22.86 Mn |
| Sep 30, 2024 | -21.38 Mn |
| Jun 30, 2024 | -28.34 Mn |
| Mar 31, 2024 | -18.02 Mn |
| Dec 31, 2023 | -19.42 Mn |
| Sep 30, 2023 | -23.29 Mn |
| Jun 30, 2023 | -19.52 Mn |
| Mar 31, 2023 | -16.32 Mn |
| Dec 31, 2022 | -46.31 Mn |
| Sep 30, 2022 | -18.63 Mn |
| Jun 30, 2022 | -17.30 Mn |
| Mar 31, 2022 | -18.25 Mn |
| Dec 31, 2021 | -963,000.00 |
| Sep 30, 2021 | -8.11 Mn |
| Jun 30, 2021 | -5.39 Mn |